Exelixis

Exelixis, Inc.
FormerlyExelixis Pharmaceuticals, Inc.
(1994-2000)
TypePublic
IndustryBiotechnology
FoundedNovember 1994 (1994-11)
HeadquartersAlameda, California, U.S.
Key peopleStelios Papadopoulos, Ph.D. (chairman)
Michael M. Morrissey, Ph.D. (president & CEO)
RevenueIncrease US$ 2.32 Billion (2025)
Increase US$ 0.872 Billion (2025)
Increase US$ 0.783 Billion (2025)
Total assetsIncrease US$ 2.844 Billion (2025)
Total equityIncrease US$ 2.161 Billion (2021)
Number of employees
1,077 (2025)
Websiteexelixis.com
Footnotes

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.